不可切除肝细胞癌患者高危静脉曲张无创检测模型的开发与验证
本研究为美国21中心回顾性队列,纳入2007至2019年不可切除肝细胞癌且Child-Pugh A5-B7肝硬化、在索引影像后12个月内且肝癌治疗前完成食管胃十二指肠镜的成人患者707例,按70:30分为训练集与验证集,以最大化阴性预测值为目标开发并验证无创静脉曲张预测模型。
要点
- 验证队列中,仅用临床变量的模型阴性预测值为86.3%,联合临床与影像变量的模型为97.4%。
- 联合模型可在超过半数低危患者中避免食管胃十二指肠镜,但将7.7%高危患者错误分类。
- 从肝癌诊断到食管胃十二指肠镜的中位时间为47天(四分位距114天),25.0%患者存在高危静脉曲张。
核心结论
- 整合临床与影像数据的模型可准确预测肝细胞癌患者不存在高危静脉曲张,并在开始全身治疗前使许多低危患者避免食管胃十二指肠镜,从而加快诊疗并避免治疗延迟。
研究设计与样本
- 美国21中心回顾性队列研究,纳入2007至2019年诊断的不可切除肝细胞癌且Child-Pugh A5-B7肝硬化的成人患者,共707例。
- 纳入在索引影像后12个月内且肝癌治疗前完成食管胃十二指肠镜的患者,按70:30分为训练集与验证集,以最大化阴性预测值为目标。
主要发现
- 中位年龄64.6岁,80.6%为男性,74.0%为白人。
- 从肝癌诊断到食管胃十二指肠镜的中位时间为47天(四分位距114天),25.0%患者存在高危静脉曲张。
- 验证队列中,仅用临床变量的模型阴性预测值为86.3%,联合临床与影像变量的模型阴性预测值为97.4%。
- 联合模型可在超过半数低危患者中避免食管胃十二指肠镜,但将7.7%高危患者错误分类。
临床怎么用
- 原文结论认为,整合临床与影像数据的模型可在开始全身治疗前使许多低危患者避免食管胃十二指肠镜,从而加快诊疗并避免治疗延迟。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Noninvasive variceal risk stratification systems have not been validated in patients with hepatocellular carcinoma (HCC), which presents logistical barriers for patients in the setting of systemic HCC therapy. We aimed to develop and validate a noninvasive algorithm for the prediction of varices in patients with unresectable HCC. METHODS: We performed a retrospective cohort study in 21 centers in the United States including adult patients with unresectable HCC and Child-Pugh A5-B7 cirrhosis diagnosed between 2007 and 2019. We included patients who completed an esophagogastroduodonoscopy (EGD) within 12 months of index imaging but before HCC treatment. We divided the cohort into a 70:30 training set and validation set, with the goal of maximizing negative predictive value (NPV) to avoid EGD in low-risk patients. RESULTS: We included 707 patients (median age, 64.6 years; 80.6% male; 74.0% White). Median time from HCC diagnosis to EGD was 47 (interquartile range, 114) days, with 25.0% of patients having high-risk varices. A model using clinical variables alone achieved an NPV of 86.3% in the validation cohort, whereas a model integrating clinical and imaging variables had an NPV 97.4% in validation. The clinical and imaging model would avoid EGDs in more than half of low-risk patients while misclassifying 7.7% of high-risk patients. CONCLUSIONS: A model incorporating clinical and imaging data can accurately predict the absence of high-risk varices in patients with HCC and avoid EGD in many low-risk patients before the initiation of systemic therapy, thus expediting their care and avoiding treatment delays.
引用
- Parikh ND, Jones P, Salgia R, et al. Development and Validation of a Noninvasive Model for the Detection of High-Risk Varices in Patients With Unresectable Hepatocellular Carcinoma. Clin Gastroenterol Hepatol. 2024. PMID: 39089513. doi:10.1016/j.cgh.2024.07.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。